Brokerages Set Pfizer Inc. (NYSE:PFE) Target Price at $38.80
Shares of Pfizer Inc. (NYSE:PFE) have earned an average recommendation of “Buy” from the twenty-six ratings firms that are covering the stock. Ten investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $38.80.
Several research firms have weighed in on PFE. Jefferies Group set a $41.50 price target on Pfizer and gave the stock a “buy” rating in a research note on Thursday, July 14th. Vetr downgraded Pfizer from a “strong-buy” rating to a “buy” rating and set a $37.28 price target for the company. in a research note on Tuesday, June 28th. Deutsche Bank AG restated a “buy” rating on shares of Pfizer in a research note on Wednesday, June 15th. JPMorgan Chase & Co. set a $40.00 price target on Pfizer and gave the stock a “buy” rating in a research note on Monday, July 25th. Finally, BMO Capital Markets restated a “buy” rating and issued a $40.00 price target on shares of Pfizer in a research note on Thursday, July 21st.
A number of hedge funds have recently added to or reduced their stakes in the company. Nelson Roberts Investment Advisors LLC increased its position in Pfizer by 6.7% in the second quarter. Nelson Roberts Investment Advisors LLC now owns 2,999 shares of the biopharmaceutical company’s stock worth $106,000 after buying an additional 189 shares during the last quarter. Stelac Advisory Services LLC purchased a new position in Pfizer during the second quarter worth about $110,000. Tuttle Tactical Management LLC purchased a new position in Pfizer during the second quarter worth about $117,000. Catamount Wealth Management increased its position in Pfizer by 14.2% in the first quarter. Catamount Wealth Management now owns 4,395 shares of the biopharmaceutical company’s stock worth $130,000 after buying an additional 545 shares during the last quarter. Finally, Delphi Private Advisors LLC increased its position in Pfizer by 1.2% in the second quarter. Delphi Private Advisors LLC now owns 4,007 shares of the biopharmaceutical company’s stock worth $141,000 after buying an additional 47 shares during the last quarter. Institutional investors and hedge funds own 69.65% of the company’s stock.
Pfizer (NYSE:PFE) opened at 33.87 on Wednesday. The company’s 50 day moving average is $34.48 and its 200-day moving average is $34.04. Pfizer has a 52-week low of $28.25 and a 52-week high of $37.39. The firm has a market cap of $205.44 billion, a P/E ratio of 30.03 and a beta of 0.87.
Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.62 by $0.02. The company earned $13.10 billion during the quarter, compared to the consensus estimate of $13.01 billion. Pfizer had a return on equity of 23.37% and a net margin of 14.88%. The firm’s revenue was up 10.9% on a year-over-year basis. During the same period in the previous year, the company posted $0.56 EPS. On average, equities analysts predict that Pfizer will post $2.46 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 1st. Shareholders of record on Friday, November 11th will be paid a $0.30 dividend. The ex-dividend date is Tuesday, November 8th. This represents a $1.20 dividend on an annualized basis and a yield of 3.54%. Pfizer’s payout ratio is 95.24%.
Pfizer Company Profile
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.
Receive News & Stock Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related stocks with our FREE daily email newsletter.